Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNN3 | Q9UGI6 | 11/20 | 0.40 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.37 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2033397 | 0.78 | KCNN3 (0.52) | PDE10AKCNN3KCNN1KCNN2CCNT1 | |
| SCHEMBL19512331 | 0.74 | KCNN3 (0.38) | PDE10AMEN1KMT2AKCNN3KCNN1 | |
| SCHEMBL13263839 | 0.69 | PDE10A (0.54) | PDE10AMEN1KMT2AKCNN3KCNN1 | |
| SCHEMBL860641 | 0.68 | PDE10A (0.53) | PDE10AKCNN3KCNN1KCNN2 | |
| Ammonia Solution, Strong SCHEMBL2032435 | 0.68 | MAPKAPK2 (0.36) | KCNN3 | |
| SCHEMBL24962149 | 0.65 | PDE10A (0.46) | PDE10A | |
| SCHEMBL24962148 | 0.65 | PDE10A (0.46) | PDE10A | |
| SCHEMBL15576806 | 0.64 | KCNN3 (0.49) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL24961983 | 0.64 | PDE10A (0.47) | PDE10AKCNN3KCNN1KCNN2TMEM97 | |
| SCHEMBL29344715 | 0.63 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CDK2, CKS2, CSNK2A1 | PDE10A 3104/4885MEN1 4012/4885KMT2A 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.